– USA, NY – Cleerly, the company creating a new standard of care for heart disease, today announced the additions of Kevin King, Dr. Glenn Steele (MD, Ph.D.), and Dr. Roy Beveridge (MD) to its board of directors.
“We are pleased to welcome Roy, Kevin, and Glenn to our Board of Directors. All three join our board with highly impressive backgrounds as leaders in the healthcare space,” said founder and CEO, Dr. Jim Min. “Cleerly has grown significantly in the last year as we work to create a world without heart attacks, and we don’t have any plans to slow down. Having the right experts on our team is key for us to accomplish our goals, and our new board members impeccably fit the bill.”
Additionally, Cleerly has assembled a panel of board observers including:
- Greg Banker, VP of Vensana Capital;
- Cynthia Yee, principal at Vensana Capital;
- Dr. David Kim, managing director of DigiTX Partners;
- AJ Shimoga, senior associate at Cigna Ventures;
- Craig Cimini, managing director of Cigna Ventures.
About Kevin M. King
Kevin King has nearly three decades of experience serving in leadership roles within medical devices, digital healthcare services, and information technologies segments. For a decade, he worked at iRhythm Technologies where he led the organization as president and CEO and remains a director of the company. He has also previously served as president, CEO, and director at Affymetrix, Inc., president, and CEO of Thomson Healthcare, and a senior executive at GE Healthcare.
About Dr. Glenn D. Steele Jr.
Dr. Glenn Steele serves both as chairman of GSteele Health Solutions, an independently operated venture helping healthcare organizations create value and improve quality, and chairman of City of Hope, a national leader in advancing cancer research and treatment protocols. He is the former chairman of xG Health Solutions and former president and CEO of Geisinger Health System.
About Dr. Roy Beveridge
Dr. Roy Beveridge is currently a senior advisor at Avalere, and recently served as Humana’s chief medical officer where he led clinical policy, population health, and clinical quality initiatives. Dr. Beveridge has held similar roles for US Oncology and McKesson specialty. A medical oncologist for more than 25 years, Roy’s recent work has focused on social determinants of health and improving the health of underserved populations.
About Cleerly
Cleerly is the company creating a new standard of care for heart disease. Through value-based precision diagnostic solutions driven by machine intelligence, Cleerly enables comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for every stakeholder in the coronary care pathway.
For more information: https://cleerlyhealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
